<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/853E354C-F688-42E8-8AE3-19F77B8EA18D"><gtr:id>853E354C-F688-42E8-8AE3-19F77B8EA18D</gtr:id><gtr:name>Ministry of Health Sultanate of Oman</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Veterinary Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/853E354C-F688-42E8-8AE3-19F77B8EA18D"><gtr:id>853E354C-F688-42E8-8AE3-19F77B8EA18D</gtr:id><gtr:name>Ministry of Health Sultanate of Oman</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/52A77162-AA9C-4A2D-B8F0-18650DDBDFE9"><gtr:id>52A77162-AA9C-4A2D-B8F0-18650DDBDFE9</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>Rees</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/69E66765-94AD-42D6-8D62-DD663C59230D"><gtr:id>69E66765-94AD-42D6-8D62-DD663C59230D</gtr:id><gtr:firstName>John Stanley</gtr:firstName><gtr:surname>Gibson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901177"><gtr:id>1623546D-98A4-4B82-B2B9-477F9E47DEC5</gtr:id><gtr:title>Prevention of the complications of sickle cell disease in HbSC patients</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901177</gtr:grantReference><gtr:abstractText>Sickle cell disease (SCD) is a very common inherited condition with debilitating consequences. It results from the inheritance of an abnormal haemoglobin, the oxygen-carrying pigment of red blood cells. SCD patients have HbS, rather than the normal HbA, in their red cells. Patients may have only HbS (HbSS genotype) but other combinations are possible. The second most common is co-inheritance of HbS with a second abnormal Hb, HbC (HbSC genotype). In this case, patients? red cells contain equal amounts of HbS and HbC. HbSC disease represents about 1/3rd of the cases of SCD, with about 80,000 born annually worldwide. In all cases of SCD, red cell HbS aggregates into rigid rods when oxygen levels in the circulation are low, distorting red cell shape, making them sticky and fragile, thus reducing red cell longevity. It also encourages blockage of small blood vessels leading to organ damage and ultimately untimely death. A range of complications are seen: chronic anaemia plus symptoms of vascular occlusion (including stroke, damage to bone, retina, kidneys and lungs). This is true for HbSC individuals as well as HbSS ones. However, the disease in HbSC patients is significantly different with a different range of complications and different blood cell picture. This means that they should be considered as a discrete subset of SCD patients. Notwithstanding there is very little research pertaining specifically to HbSC patients. In fact, in most studies analysing the abnormal behaviour of red cells containing HbS and also clinical trials of potential new treatments, HbSC patients are specifically excluded. It is likely that the course of HbSC disease differs and that this results from a different abnormalities in the behaviour of their red cells. Central to this difference is the fact that the red cells contain both HbS and HbC. This work will study specifically HbSC patients. The behaviour of their red cells (containing both HbS and HbC) will be correlated with disease severity. Specific ways of stopping HbS polymerisation in HbSC red cells will be sought. Results will enable better management of HbSC patients and amelioration of the complications of SCD in this significant group of patients.</gtr:abstractText><gtr:technicalSummary>Sickle cell disease (SCD) is one of the most common severe inherited disorders but specific treatments are lacking and the pathophysiology remains unclear. Approximately 250,000 SCD babies are born annually. Incidence in the UK amounts to around 12-15,000 individuals. Affected individuals have a mutated a globin gene resulting in the presence of an abnormal haemoglobin Hb, HbS, in their red blood cells. Whilst about two-thirds of SCD patients are homozygous HbSS individuals, patients heterozygous for HbS and a second Hb mutation HbC (ie HbSC heterozygotes) constitute about one-third of SCD cases, making HbSC disease the second most common form of SCD in UK and worldwide. In HbSC patients, red cells contain equal amounts of HbS and HbC. The complications of SCD are extensive, many resulting from the tendency of HbS to polymerise into long rigid rods on deoxygenation. Importantly, red cells from all SCD patients have an abnormal permeability, lose solutes and shrink, raising their total [Hb]. This markedly encourages HbS polymerisation. Patients? red cells have a reduced lifespan and are less able to traverse small blood vessels, causing chronic anaemia, microvascular occlusion and ischaemia affecting many organs. Although many symptoms are common to both, the condition is not identical in SCD patients of HbSS and HbSC genotypes. Disease complications and haematological findings differ. As such, HbSC disease should be treated as a discrete subset of SCD patients. Currently there is very little specific information on the pathophysiology and management of HbSC disease, with most knowledge being inferred from studies of HbSS. Differences in pathogenesis between HbSC and HbSS disease are expected. Understanding them will be important directly to the management of HbSC patients, and may also contribute to a better appreciation of HbSS disease. We hypothesise that the transport properties of red cells from HbSC patients differ significantly from those of HbSS individuals, accounting for the different symptoms observed of this group of patients, and enabling the design of unique therapeutic regimes to ameliorate HbSC disease. Preventing solute loss and deoxygenation-induced HbS polymerisation is more feasible in red cells from HbSC patients because their reduced content of HbS means that only a modest increase in cell hydration is required. We aim to understand solute loss in HbSC red cells in order to reduce ion permeability and thus achieve this greater degree of hydration.</gtr:technicalSummary><gtr:fund><gtr:end>2013-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>482799</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Molecular Haematology</gtr:department><gtr:description>Proteomics for identification of the deoxygenation-induced cation conductance of sickle cells</gtr:description><gtr:id>5BE7782D-3538-4ED1-9B15-9791A5ECE845</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>MDL3STtKyLt-1</gtr:outcomeId><gtr:partnerContribution>Establishment of proteomics matrix</gtr:partnerContribution><gtr:piContribution>Provision of samples and design of assay</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Molecular Haematology</gtr:department><gtr:description>Managing children with sickle cell nephropathy</gtr:description><gtr:id>1238B32E-B225-43AC-85F2-CFB59AD0DB7C</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>agiWTnmDAHs-1</gtr:outcomeId><gtr:partnerContribution>Consent children and provide samples, analyse clinical data</gtr:partnerContribution><gtr:piContribution>We are measuring prognostic indicators of red blood cell phenotype to predict development of renal disease in children</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ministry of Health Sultanate of Oman</gtr:collaboratingOrganisation><gtr:country>Oman, Sultanate of</gtr:country><gtr:description>Pathogenesis of HbS-Oman</gtr:description><gtr:id>CD002474-43D5-4AEA-8C96-FA98D7D566EC</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>54db1e2884fea9.64679743-1</gtr:outcomeId><gtr:partnerContribution>This is just starting, but the aim is to identify prognostic measures and also potential therapeutic interventions. This population is poorly typed. Some have high levels of HbF but it is not known why - we hope to establish the cause.</gtr:partnerContribution><gtr:piContribution>We will assess the phenotype of red cells and genotype of individuals of different subsets of patients with sickle cell disease in Oman</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Integrative Physiology</gtr:department><gtr:description>Altered regulation of cation cotransporter in sickle cells</gtr:description><gtr:id>0E749556-4286-4782-917B-9D9502D4B35C</gtr:id><gtr:impact>None but publication pending</gtr:impact><gtr:outcomeId>qFVih9sm9Gi-1</gtr:outcomeId><gtr:partnerContribution>Analysis of phosphorylated targets concerned with cotransporter regulation</gtr:partnerContribution><gtr:piContribution>Novel assay for investigating cotransporter control in normal and sickle red cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Visit from year 13 school student</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2B908659-3242-40FF-AABE-188E3FE735CD</gtr:id><gtr:impact>Interest in applying to science courses at university

Stimulate application to university</gtr:impact><gtr:outcomeId>561ba480b854d7.64524203</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sickle cell conference at KCH London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E658DE2E-7E80-4424-86C2-F45D3E964B87</gtr:id><gtr:impact>200 delegates attended generating discussion about red cell problems in sickle cell disease

Email contact</gtr:impact><gtr:outcomeId>TUKmK1C9bi7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sickle cell conference KCH London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AC797527-B295-4D7F-9E76-BD08906DE545</gtr:id><gtr:impact>Audience of 250 healthcare workers including clinicians, nurses and research workers interested in care of sickle cell patients. Contributed to talk on biomarkers.

Interest in haemolysis test</gtr:impact><gtr:outcomeId>LkXnU4ve77r</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Purdue University, USA.  Talk to researchers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9B61E5D0-1120-492F-B6B1-6844E233E8E0</gtr:id><gtr:impact>Discussion afterwards about novel therapies for sickle cell disease including targeted left shift reagents, with anion exchanger affinity to focus on red cells.

Interest from colleagues</gtr:impact><gtr:outcomeId>54db21b74e7910.78303612</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit from year 12 school student</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>77F93D90-35C7-4C7D-A7F8-FBB174BBF5E8</gtr:id><gtr:impact>Interest in science

School asked for pupils to attend my lab for work experience</gtr:impact><gtr:outcomeId>561ba42681e167.72856771</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Charity fund raising</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9A6A5293-5703-421C-8177-B487E48DD45D</gtr:id><gtr:impact>50 people listened to invited talks about research funded by the charity

Interested feedback</gtr:impact><gtr:outcomeId>akCGRPwtc1a</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to year 12 students</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>12B29E4B-D53E-44DF-A287-45EBFFE169B3</gtr:id><gtr:impact>25 school students attended and asked questions about role of red cells, oxygen delivery and sickle cell disease.

Encourage applications to Cambridge</gtr:impact><gtr:outcomeId>HCzKMjWCsFd</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Society for Red Cell Research:  Roscoff</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5B41016F-7082-402D-9723-6A1CE4B2E00E</gtr:id><gtr:impact>Discussion

Research collaborations</gtr:impact><gtr:outcomeId>561ba3598974f8.07344641</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference at Yale, New Haven, American Red Cell Club</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>698C380F-222D-4D46-B5DB-92372B8402C9</gtr:id><gtr:impact>Discussion

Collaborations</gtr:impact><gtr:outcomeId>561ba4c018b709.68847607</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference in Copenhagen, European Haematology Association</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E8300B13-C547-4EBB-B05A-885A4B1DB7AE</gtr:id><gtr:impact>Discussion and potential collaborations. Dissemination of information pertinent to care of patients with sickle cell disease

Clinical interest</gtr:impact><gtr:outcomeId>56693c292d9df2.22476120</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit from year 12 school student</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A0A89B9D-5DEA-402E-85A5-23E64A09F3D5</gtr:id><gtr:impact>Interest in career in science

School asked if GCSE pupils could visit my lab</gtr:impact><gtr:outcomeId>561ba3c10c4d49.42498577</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>219000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research project: Phosphatidylserine exposure in red blood cells from patients with sickle cell disease: calcium and oxidants</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>31966</gtr:fundingRef><gtr:id>72121E59-8EB6-46D7-8A0E-363195D0C7DE</gtr:id><gtr:outcomeId>56c70583a0f0a6.65720391</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>47000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Diagnosis and prognosis of sickle cell disease</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Action Medical Research</gtr:fundingOrg><gtr:id>C1FA2E9C-C7CF-48EB-908A-CEF397352D0B</gtr:id><gtr:outcomeId>mC28AbXUEa60</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sheik Jameel Studentship</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>0838C85D-3489-4FE1-8607-38616DBF7C32</gtr:id><gtr:outcomeId>BR8PqXpnMZx</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Studentship</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>6046CD4D-1082-49F3-8FC1-A736CAF9437F</gtr:id><gtr:outcomeId>dSVnTstnweT</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>209000</gtr:amountPounds><gtr:country>Oman, Sultanate of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pathogenesis of HbS-Oman</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Ministry of Health Sultanate of Oman</gtr:fundingOrg><gtr:id>85A9375F-956B-4E05-B40A-744F3C051311</gtr:id><gtr:outcomeId>54db1ebd965ef6.49025631</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91290</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant: Sickle cell disease and renal complications</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Action Medical Research</gtr:fundingOrg><gtr:fundingRef>GN2030</gtr:fundingRef><gtr:id>D6BAB2FB-4B97-4CB7-B8FD-893974B7A230</gtr:id><gtr:outcomeId>hfxgHxL7U1s</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Use of deoxygenated or low pH isosmotic non-electrolyyte solution for simpler diagnosis and potential prognosis of sickle cell disease</gtr:description><gtr:id>ACC6AF4A-AD1B-4157-94BB-52EEF4AD90B3</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>mf9zno5JyZH</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Haemolytic assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Lysis material from red blood cells</gtr:description><gtr:id>C720D54B-D922-44FD-87A6-714A1F314F56</gtr:id><gtr:impact>Attempt to identify Psickle, a key transport pathway implicated in the pathogenesis of sickle cell disease, whose molecular identity has not been established. Also identification of key regulatory enzymes in control of KCl cotransport activity. Finally, particular KCl cotransport isoforms involved in the disease</gtr:impact><gtr:outcomeId>ZAUxEbQ54VN</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Proteomics for identification of Psickle</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0CFBA2D2-09C5-4810-B79F-D3AF0E282C30</gtr:id><gtr:title>Inhibitors of second messenger pathways and Ca(2+)-induced exposure of phosphatidylserine in red blood cells of patients with sickle cell disease.</gtr:title><gtr:parentPublicationTitle>Pflugers Archiv : European journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/893d7805d7c10a818c8ebfc59d3b7f89"><gtr:id>893d7805d7c10a818c8ebfc59d3b7f89</gtr:id><gtr:otherNames>Gbotosho OT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-6768</gtr:issn><gtr:outcomeId>545b76373da273.72291565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B7FE944-43F4-4421-BEAB-B2FE75546D49</gtr:id><gtr:title>The clinical significance of K-Cl cotransport activity in red cells of patients with HbSC disease.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d87bbb151f620b5be31a47d880b829"><gtr:id>a5d87bbb151f620b5be31a47d880b829</gtr:id><gtr:otherNames>Rees DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>561ba54c103f25.90365150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0DE2C96-0792-4566-8198-15EFA16BDF91</gtr:id><gtr:title>Cation Homeostasis in Red Cells From Patients With Sickle Cell Disease Heterologous for HbS and HbC (HbSC Genotype).</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/216e8ac378e80b653ddf287eb4d24bf5"><gtr:id>216e8ac378e80b653ddf287eb4d24bf5</gtr:id><gtr:otherNames>Hannemann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>56693975ef6199.12194211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55A19239-BF86-4CBB-AEE3-E876916CB5EB</gtr:id><gtr:title>Effect of hydroxyurea on potassium permeability of red blood cells from sickle cell patients</gtr:title><gtr:parentPublicationTitle>Annals of Hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7be6621d0c8b7530670a4078b331254f"><gtr:id>7be6621d0c8b7530670a4078b331254f</gtr:id><gtr:otherNames>Hannemann Anke</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>JNUUtDHX7nC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2482EFB3-B858-4B2F-BB6A-DDA11E533D37</gtr:id><gtr:title>Novel permeability characteristics of red blood cells from sickle cell patients heterozygous for HbS and HbC (HbSC genotype).</gtr:title><gtr:parentPublicationTitle>Blood cells, molecules &amp; diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8949cf58f0affa40b49c7c91953a4d8"><gtr:id>d8949cf58f0affa40b49c7c91953a4d8</gtr:id><gtr:otherNames>Dalibalta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1079-9796</gtr:issn><gtr:outcomeId>eaRxF9b9s7M</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C7A86ED-BB8E-4303-BEBB-4FB3518286C4</gtr:id><gtr:title>Effects of 5-hydroxymethyl-2-furfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/216e8ac378e80b653ddf287eb4d24bf5"><gtr:id>216e8ac378e80b653ddf287eb4d24bf5</gtr:id><gtr:otherNames>Hannemann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>545b7723b3f313.79104477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53C882C7-4070-467F-AB91-564CC0DAAF00</gtr:id><gtr:title>Role of calcium in phosphatidylserine externalisation in red blood cells from sickle cell patients.</gtr:title><gtr:parentPublicationTitle>Anemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6e38d927d1d4d45eeb93ec5636a2230"><gtr:id>d6e38d927d1d4d45eeb93ec5636a2230</gtr:id><gtr:otherNames>Weiss E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2090-1267</gtr:issn><gtr:outcomeId>faEguVbGtKV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6147CA00-2BE9-4B22-BD24-408FCBE961E3</gtr:id><gtr:title>SICKLE CELL DISEASE AND 5-HMF: THE SEARCH FOR EFFECTIVE TREATMENTS</gtr:title><gtr:parentPublicationTitle>DRUGS OF THE FUTURE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e00e06e0d5265828cb31c701fcc4a83"><gtr:id>4e00e06e0d5265828cb31c701fcc4a83</gtr:id><gtr:otherNames>Gibson J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0377-8282</gtr:issn><gtr:outcomeId>56c7045e556ff6.52969606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AAB8078-05A5-4576-B00C-721FD65D286F</gtr:id><gtr:title>The Properties of Red Blood Cells from Patients Heterozygous for HbS and HbC (HbSC Genotype).</gtr:title><gtr:parentPublicationTitle>Anemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/216e8ac378e80b653ddf287eb4d24bf5"><gtr:id>216e8ac378e80b653ddf287eb4d24bf5</gtr:id><gtr:otherNames>Hannemann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2090-1267</gtr:issn><gtr:outcomeId>tKNmTFpoJZr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32E13E1F-5161-4E9B-8E67-97153C715EE9</gtr:id><gtr:title>Biomarkers in sickle cell disease.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d87bbb151f620b5be31a47d880b829"><gtr:id>a5d87bbb151f620b5be31a47d880b829</gtr:id><gtr:otherNames>Rees DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_13936_26_22122125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A89494C8-62DC-4F5F-A46A-071459296F22</gtr:id><gtr:title>Deoxygenation-induced and Ca(2+) dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients.</gtr:title><gtr:parentPublicationTitle>Cell calcium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6e38d927d1d4d45eeb93ec5636a2230"><gtr:id>d6e38d927d1d4d45eeb93ec5636a2230</gtr:id><gtr:otherNames>Weiss E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0143-4160</gtr:issn><gtr:outcomeId>pm_13936_26_22197026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D4DA6E1-ABA8-439C-8306-1AB9D7089AC8</gtr:id><gtr:title>How benign is sickle cell trait?</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e43f3419fb7af6c9dbca8fcaa3f91076"><gtr:id>e43f3419fb7af6c9dbca8fcaa3f91076</gtr:id><gtr:otherNames>Gibson JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>58aafade9dcce0.59364034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9094D73-BEEA-499D-A280-01926FA4C5DD</gtr:id><gtr:title>A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7096513c665b53efd94bc72705eec751"><gtr:id>7096513c665b53efd94bc72705eec751</gtr:id><gtr:otherNames>Milligan C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>pm_13936_26_23297308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FA7DBB4-75C0-41ED-B21C-300556DDD8C3</gtr:id><gtr:title>Effects of o-vanillin on K? transport of red blood cells from patients with sickle cell disease.</gtr:title><gtr:parentPublicationTitle>Blood cells, molecules &amp; diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/216e8ac378e80b653ddf287eb4d24bf5"><gtr:id>216e8ac378e80b653ddf287eb4d24bf5</gtr:id><gtr:otherNames>Hannemann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1079-9796</gtr:issn><gtr:outcomeId>545b769dc0a1f1.21205913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B50A83D-5A5C-4614-AA17-180B0591EAE1</gtr:id><gtr:title>The conductance of red blood cells from sickle cell patients: ion selectivity and inhibitors.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f4295deb1b9aa0d8f7c9e9781140361"><gtr:id>2f4295deb1b9aa0d8f7c9e9781140361</gtr:id><gtr:otherNames>Ma YL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>pm_13936_26_22411011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC9565FD-B91F-44F9-8AB5-F2EA2F7590D1</gtr:id><gtr:title>Nocturnal enuresis and K+ transport in red blood cells from patients with sickle cell anemia.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78601b270797c202e821ef852cca3396"><gtr:id>78601b270797c202e821ef852cca3396</gtr:id><gtr:otherNames>Tewari S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>58aafabb5aeb76.29627604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0951490E-8D1F-4C4C-B9DF-FEDEC3D31F94</gtr:id><gtr:title>Identification of the Ca&amp;sup2;? entry pathway involved in deoxygenation-induced phosphatidylserine exposure in red blood cells from patients with sickle cell disease.</gtr:title><gtr:parentPublicationTitle>Pflugers Archiv : European journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6172a2dd6c312a0e60a67515539a740"><gtr:id>f6172a2dd6c312a0e60a67515539a740</gtr:id><gtr:otherNames>Cytlak UM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0031-6768</gtr:issn><gtr:outcomeId>pm_13936_26_23775402</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901177</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>